SULFAGENIX

Sulfagenix and its wholly-owned subsidiary, Sulfagenix Australia, are built on decades of research on modifying existing molecules to improve safety, bioavailability, and efficacy for new uses. SG1002, the company’s lead molecule, is a precursor to a natural-occurring molecule, hydrogen sulfide, for which deficits have been shown to exist in a number of serious diseases, including cardiovascular disease, type II diabetes, cancer, hypertension, Alzheimer’s Disease, asthma, and wound healing. ... In addition, sulfur deficiencies in the diet may be directly contributing to these diseases. Patient studies in Mexico demonstrated safety and generated encouraging results in several disease conditions including infertility, cancer, and hypercholesterolemia. Sulfagenix’s lead product, SG1002, is being developed in Phase I clinical trial (http://www.clinicaltrials.gov/ct2/show/NCT01989208) in Australia by Sulfagenix Australia to treat problems associated with heart failure.More